Skip to main content
. 2021 Nov 5;52(1):29–38. doi: 10.1093/jjco/hyab170

Figure 2.

Figure 2

Rates of CR and CR+CRi (a), and investigator-assessed event-free survival (b). aStratified by age (18 to <75, ≥75 years) and cytogenetic risk (intermediate, poor). Aza, azacitidine; CI confidence interval; CR, complete response; CRi, CR with incomplete blood count recovery; HR, hazard ratio; Pbo, placebo; Ven, venetoclax.